Table 1 Clinical and laboratory characteristics of ankylosing spondylitis patients, with high and low disease activity and controls
High disease activity (BASDAI ≥ 4) | Low disease activity (BASDAI < 4) | Healthy controls | |
|---|---|---|---|
n = 50 | n = 28 | n = 23 | |
age in years (SD) | 37.8 (11.6)*& | 32.0 (6.6) | 32.3 (7.5) |
disease duration in years (SD) | 9.0 (6.7) | 7.2 (5.0) | NA |
BASDAI (SEM) | 7.17 (0.24)* | 2.79 (0.15) | NA |
ESR mm/hr (SEM) | 34.7 (3.09)*& | 21.3 (3.74)& | 6.3 (0.79) |
CRP mg/l (SEM) | 23.4 (3.87)*& | 10.7 (2.24) & | 0.89 (0.16) |
TNF alpha pg/ml (SEM) | 2.03 (0.19) & | 2.56 (0.74) & | 1.77 (0.24) |
IL-6 pg/ml (SEM) | 6.01 (1.53) & | 4.4 (0.66) & | 0.80 (0.007) |
IL-18 pg/ml (SEM) | 446.25 (30.62) | 418.0 (28.2) | 394.0 (21.8) |
Dkk-1 pg/ml (SEM) | 818.7 (114.9)* & | 1692.7 (122.3) & | 1349.3 (82.7) |
sclerostin ng/ml (SEM) | 0.34 (0.09) & | 0.21 (0.12) | 0.12 (0.09) |
Wnt-3a ng/ml (SEM) | 12.6 (2.46)* & | 26.3 (2.24) & | 16.9 (2.4) |
BMP-7 pg/ml (SEM) | 5.46 (0.92) | 5.67 (0.97) | 5.6 (1.09) |
MMP-3 ng/ml (SEM) | 11.6 (2.46)* & | 56.1 (36.7) | 13.1 (1.28) |
OPG pmol/ml (SEM) | 4.8 (0.34) & | 4.0 (0.21) | 3.9 (1.16) |
BALP U/l (SEM) | 76.9 (9.15) | 57.7 (3.36) | 53.4 (8.0) |
mSASSS | 8 (4-51) | 8 (1-22) | NA |
median (5–95 percentile) |